Seattle-based Cyrus Biotechnology says it’ll collaborate with the Broad Institute of MIT and Harvard on ways to optimize CRISPR gene-editing techniques for use in developing novel human therapeutics. Cyrus Biotech and the Broad Institute will work on ways to reduce the potential for the body to mount an immune response against CRISPR-based therapies. MIT biochemist Feng Zhang, one of the pioneers in the development of CRISPR, will be the principal investigator for the effort at the Broad Institute. The results of the collaboration will be published in peer-reviewed journals and made freely available to the academic and non-profit scientific community. Learn More